Collagen matrix flap covalently bound with fibroblast growth factor and preparation method thereof
By covalently combining collagen with oxidized sodium alginate and loading alkaline fibroblast growth factor with polyamide-amine dendrimers, the long surgical time and insufficient performance of alternative materials in gingival recession treatment are solved, and efficient Gingival tissue regeneration and long-term sustained release effects.
Patent Information
- Application Number
- CN202411166772.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The existing treatments for gingival recession have problems such as long surgery time, postoperative discomfort, high complication risk, and insufficient volume stability and degradation speed of alternative materials. The soft tissue replacement materials on the market are high, and the existing growth factor loading rate Not high problem.
Crosslinking with oxidized sodium alginate by collagen and using polyamide-amine under the action of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and N-hydroxysuccinimide Dendritic polymers covalently load basic fibroblast growth factors to construct covalently bound collagen matrix valves to enhance the sustained release effect of growth factors.
It achieves higher growth factor grafting efficiency and sustained release effect, promotes regeneration and repair of gingival tissue, provides better clinical operability and cell proliferation activity, has a sustained release effect of 28 days, and the mechanical properties of the material are good.
Smart Images

Figure CN119034008A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of collagen-based scaffolds, and in particular to a collagen matrix flap covalently bound with a fibroblast growth factor and a preparation method thereof. Background Art
[0002] At present, the main periodontal soft tissue regeneration surgery for the treatment of gingival recession in clinical practice is coronally advanced flap (CAF) combined with subepithelial connective tissue graft (SCTG) or biological substitute materials. SCTG is considered to be the standard method for the treatment of gingival recession. Compared with the use of CAF alone, it can more effectively maintain the stability of the gingival margin. However, autologous grafts need to be harvested from the palate or maxillary tuberosity, which increases the operation time and postoperative discomfort, and may also cause complications such as bleeding, infection and sensory disturbance in the donor site. In addition, since the amount of material is limited by anatomical structures such as the greater palatine neurovascular bundle, the problem of insufficient grafts may be faced when treating gingival recession of multiple teeth. Insufficient palatal mucosal thickness will also increase the risk of postoperative complications. Compared with SCTG, the development of new soft tissue substitute materials is a promising direction, but the existing substitute materials still have certain defects in terms of volume stability and degradation rate. In addition, most of the soft tissue substitute materials on the market are imported products with high prices, which brings economic burden to patients.
[0003] Growth factors can promote cell proliferation and tissue repair and regeneration, and are one of the important elements of tissue engineering. In terms of application, they are mainly divided into enriched natural growth factors, such as various concentrated membranes rich in plasma components and growth factors represented by platelet-rich fibrin (PRF), and recombinant human growth factors. Compared with CAF alone, the use of PRF as a replacement graft has a better performance in reducing gingival recession; but compared with the treatment effect of CAF combined with SCTG, it has significant deficiencies in root coverage and keratinized tissue thickening. In addition, its production process lacks standardized preparation and application specifications, and its quality is greatly affected by production equipment. Basic fibroblast growth factor (bFGF) has been proven to play an important role in angiogenesis, immune regulation, tissue regeneration and wound healing. Studies have shown that the combination of recombinant basic human fibroblast growth factor and scaffold materials in the canine gingival recession model can obtain more new bone and new connective tissue, and has the potential to improve root coverage. However, its effect in improving gingival recession still needs long-term verification. As described in patent CN101962409B, collagen and growth factors are directly combined together by covalent means. However, due to the limited amino groups of collagen, there is still a problem of low growth factor loading rate. Summary of the invention
[0004] In view of the defects existing in the above-mentioned background technology, the purpose of the present invention is to provide a collagen matrix flap covalently bound to fibroblast growth factor and a preparation method thereof. In the preparation process of the collagen matrix flap, collagen is cross-linked with oxidized sodium alginate, and after cross-linking, more basic fibroblast growth factor is covalently loaded and its sustained release effect is enhanced by grafting amino-rich polyamide-amine dendrimers under the action of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS).
[0005] The present invention is achieved by the following technical methods:
[0006] A method for preparing a collagen matrix flap covalently bound with fibroblast growth factor, the method comprising the following steps:
[0007] (1) Oxidized sodium alginate (OSA) was synthesized by periodate oxidation. 5 g of sodium alginate was weighed and dissolved in 200 ml of deionized water under magnetic stirring for a long time, and then 5 g of sodium periodate was added. The mixture was stirred at 25-37°C in the dark for 2-4 h, and then 5 mL of ethylene glycol was added to suspend and react for at least 0.5 h. The reactant was then dialyzed, frozen and lyophilized to obtain OSA.
[0008] (2) OSA-Col scaffolds with a collagen concentration of 8 mg / ml and a mass ratio of OSA to collagen of 4-20:100 (w / w) were prepared by the following method: first, bovine type I collagen was dissolved in 0.5 M acetic acid solution at 4°C, and the pH was adjusted to neutral with 2 M NaOH solution. At the same time, OSA was dissolved in PBS (pH = 7.4). The OSA and Col solutions were mixed for 30 minutes, and the amino groups of collagen were cross-linked with the aldehyde groups of OSA through Schiff base, and then centrifuged to remove bubbles. Subsequently, each 2.5 ml of the mixture solution was transferred to a fixed-size mold with a length of 18 mm, a width of 23 mm, and a thickness of 6 mm. The mixture was incubated in an oven at 37°C for more than 4 hours for the self-assembly process, and then frozen at -20°C overnight. After freeze-drying, a collagen cross-linked oxidized natural polysaccharide scaffold (abbreviated as OSA-Col scaffold) was obtained. Among them, too low collagen concentration and OSA / Col mass ratio will affect the mechanical strength of the gel, and too high collagen concentration and OSA / Col mass ratio will form an overly dense pore structure, affecting the migration and ingrowth of cells and the excretion of cell metabolites during soft tissue healing. Therefore, the optimal collagen concentration is determined to be 8 mg / ml and the mass ratio of OSA to Col is 16:100 in this application.
[0009] (3) The previously obtained fixed-size OSA-Col scaffold was immersed in a 50 mM MES buffer solution (pH = 5.5), the MES buffer solution contained a polyamidoamine dendrimer (PAMAM) at a concentration of 5-20 mg / ml, a bFGF at a concentration of 50-150 ng / ml, and then 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (at a concentration of 5 mM) and N-hydroxysuccinimide (NHS) (at a concentration of 5 mM) were added for cross-linking reaction. The pH was adjusted to 5.5 using NaOH or HCl, and the resulting solution was incubated at 4°C for 24 hours. Then, it was washed with deionized water for 30 minutes and freeze-dried at -20°C to obtain the collagen matrix flap covalently bound to fibroblast growth factor (i.e., P-OSA-Col@bFGF scaffold, referred to as POC@bFGF).
[0010] Among them, too low PAMAM concentration cannot effectively increase the number of collagen amino groups and thus improve the grafting efficiency, while too high PAMAM concentration may also produce steric hindrance and polycationic effect, which will reduce the grafting and sustained release efficiency of growth factors. In addition, too low growth factor concentration does not play a biological role in promoting cell proliferation, and too high growth factor concentration does not bring higher cell proliferation effect, but may bring cytotoxic side effects. Therefore, in the process of preparing the scaffold, the PAMAM concentration and the growth factor concentration need to be strictly controlled within a suitable concentration range. In addition, the application also determines that the optimal PAMAM concentration for biological scaffold grafting is 10mg / ml, and the optimal concentration of bFGF is 100ng / ml.
[0011] The present invention also provides a collagen matrix flap prepared by the above method.
[0012] The inventive principle of the present invention is:
[0013] In view of the problem of too fast metabolism rate when directly using growth factors, the present invention designs materials to encapsulate and fix growth factors in the form of scaffolds, and constructs a growth factor delivery system to achieve a long-term sustained release effect. Type I collagen can enhance mechanical properties by cross-linking and oxidizing sodium alginate, and can further increase the grafting efficiency of growth factors by grafting polyamide-amine dendrimers. On the basis of retaining collagen activity, growth factors are covalently grafted and sustained release in vivo is achieved through material degradation. Therefore, the present invention intends to graft fibroblast growth factor on materials with good biocompatibility and moderate degradation rate to construct a cell-responsive soft tissue replacement material to promote gingival tissue regeneration and repair.
[0014] The present invention has the following advantages:
[0015] (1) Compared with the scaffold physically mixed with growth factors (POC+bFGF), the grafting efficiency of the scaffold of the present invention for fibroblast growth factor is higher, and the grafting efficiency is highest when the PAMAM concentration is 10 mg / ml;
[0016] (2) Compared with the scaffold physically mixed with growth factors, the scaffold of the present invention can achieve a sustained release effect of up to 28 days, and the sustained release effect is best when the PAMAM concentration is 10 mg / ml;
[0017] (3) Compared with the biological scaffold without fibroblast growth factor, the scaffold loaded with fibroblast growth factor of the present invention has stronger cell proliferation promoting activity when the growth factor concentration is 100 ng / ml;
[0018] (4) Compared with the non-oxidative natural polysaccharide cross-linked biological scaffold (Col), the scaffold of the present invention has good mechanical properties and better clinical operability. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Schematic diagram of the preparation principle of the stent of the present invention;
[0020] Figure 2 Fourier transform infrared spectra of the stent prepared by the method of the present invention and the stent of the control group;
[0021] Figure 3 The microscopic morphology and pore size distribution of the scaffold prepared by the method of the present invention and the scaffold of the control group;
[0022] Figure 4 is the swelling rate of the scaffold prepared by the method of the present invention and the scaffold of the control group;
[0023] Figure 5 The amino concentration of the PAMAM scaffold grafted with different concentrations according to the method of the present invention;
[0024] Figure 6 is the growth factor loading rate of bFGF grafted on the scaffolds of each group;
[0025] Figure 7 This is the 28-day growth factor sustained-release curve of each group of scaffolds;
[0026] Figure 8 The shear and cyclic compression properties of the stent prepared by the method of the present invention and the stent of the control group;
[0027] Fig. 9 The CCK-8 cell proliferation activity of the scaffold prepared by the method of the present invention and the scaffold of the control group;
[0028] Fig.10 These are the cell live-dead staining results of the scaffold prepared by the method of the present invention and the scaffold of the control group. DETAILED DESCRIPTION
[0029] The technical solution of the present invention is further described below with reference to examples.
[0030] A method for preparing a collagen matrix flap covalently bound to fibroblast growth factor, the preparation principle is as follows Figure 1 , specifically including the following steps:
[0031] (1) Oxidized sodium alginate (OSA) was synthesized by periodate oxidation method. 5 g of sodium alginate was weighed and dissolved in 200 ml of deionized water under magnetic stirring for a long time, and then 5 g of sodium periodate was added. The mixture was stirred in the dark at 25-37°C for more than 4 h, and then 5 mL of ethylene glycol was added to suspend and react for 0.5 h. The reactant was then dialyzed, frozen and lyophilized to obtain OSA.
[0032] (2) To prepare an OSA-Col scaffold with a final collagen concentration of 8 mg / ml and an OSA / Col mass ratio of 4-20:100 (w / w), bovine type I collagen was first dissolved in a 0.5 M acetic acid solution at 4°C, and the pH was adjusted to neutral with a 2 M NaOH solution. At the same time, OSA was dissolved in PBS (pH = 7.4). The OSA and Col solutions were mixed for 30 minutes and then centrifuged to remove bubbles. Subsequently, each 2.5 ml of the mixture solution was transferred to a fixed-size mold with a length of 18 mm, a width of 23 mm, and a thickness of 6 mm. The mixture was incubated in an oven at 37°C for 4 hours and then frozen at -20°C overnight. After freeze-drying, an OSA-Col scaffold was obtained.
[0033] (3) To prepare the scaffold, the previously obtained fixed-size OSA-Col scaffold was immersed in 10 ml of a 50 mM MES buffer solution (pH = 5.5) containing a solution of 5-20 mg / ml PAMAM, 50-150 ng / ml bFGF, 5 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), and 5 mM N-hydroxysuccinimide (NHS). The pH was adjusted to 5.5 using NaOH or HCl, and the resulting solution was incubated at 4 °C for 24 h. Then, it was washed with deionized water for 30 min, frozen at -20 °C overnight, and freeze-dried to obtain POC@bFGF scaffolds with different PAMAM concentrations.
[0034] In addition, as shown in Table 1, the collagen scaffolds containing or not containing OSA were immersed in 10 ml of MES buffer solution (pH = 5.5) containing different concentrations of PAMAM, bFGF and different components to obtain each group of biological scaffolds. The pH was adjusted to 5.5, and the resulting solution was incubated at 4°C for 24 hours. Then, it was washed with deionized water for 30 minutes, frozen at -20°C, and then freeze-dried to obtain experimental group scaffolds containing different PAMAM concentrations and different bFGF and other control group scaffolds.
[0035] Table 1 Composition of the scaffolds in the experimental group and the control group
[0036]
[0037] The performance of various scaffolds prepared in the above examples and control groups was tested. The test results show that the preparation process of the scaffold of the present invention does not destroy the original structural conformation of collagen, and the prepared scaffold has key properties for treating gingival recession (such as pore size distribution, swelling rate, mechanical strength, etc.), and the successful introduction of PAMAM can increase the grafting and sustained release efficiency of basic fibroblast growth factor and improve the biological activity of the scaffold.
[0038] Specifically, the performance test results of each group of brackets are as follows:
[0039] (1) Fourier transform infrared spectroscopy (FTIR-ATR): The analysis showed that both the Col sample and the bFGF-loaded sample retained the integrity of the key amide bands, including 3315 cm -1 The amide A band at 2936 cm -1 The amide B band at 1655 cm -1 Amide I band at 1545 cm -1 The amide II band at 1246 cm -1 The amide III band at the Figure 2 , indicating that chemical cross-linking and the introduction of growth factors as well as different concentrations of PAMAM did not destroy the structural integrity of collagen.
[0040] (2) Microstructural features were examined using a scanning electron microscope. Each single-layer sample with a thickness of 3 mm was sliced and its cross section was observed. A pore size analysis was performed, and the results were as follows: Figure 3 As shown, the average pore size of each group is above 150 μm, among which the pore size distribution of the P10OC@bFGF group is the most uniform.
[0041] (3) The morphological stability of the stent in the oral environment is crucial, and swelling is an important factor affecting its volume change. Figure 4 It can be seen that the Col@bFGF group and the P10OC@bFGF group reached swelling equilibrium at 30 minutes at the earliest, and the other groups reached equilibrium after 3 hours, and the swelling rate of the P10OC@bFGF group was the smallest.
[0042] (4) Since PAMAM is rich in amino groups, the ninhydrin experiment shows that the amino content increases significantly with the increase of PAMAM concentration. Figure 5 As shown in the figure, compared with the Col group, the amino groups of the samples with PAMAM concentrations of 5, 10, 15 and 20 mg / ml increased by 2, 3, 4 and 6 times, respectively. This proves the successful introduction of PAMAM and its amino groups.
[0043] (5) By Figure 6 It can be seen that the loading rate of bFGF in each group exceeded 80%, which may be due to the physical encapsulation effect of the porous structure of the scaffold and the electrostatic interaction between the scaffold and bFGF. The loading rate of bFGF in the group loaded with PAMAM was significantly higher than that of the group not loaded with PAMAM (Col@bFGF, OSA-Col@bFGF) and the scaffold physically mixed with growth factors (POC+bFGF). This shows that the amino group introduced by PAMAM additionally improves the loading efficiency of bFGF through covalent binding.
[0044] (6) By Figure 7 It can be seen that compared with the scaffold physically mixed with growth factors (POC+bFGF), the scaffold grafted with PAMAM can achieve a sustained release effect of up to 28 days. On the 7th day, a similar trend of growth factor release was observed, with the POC+bFGF group reaching a maximum release of 82.5%. During the next 28 days of observation, the release rate of the P10OC@bFGF group was the lowest, with a release rate of only 41%. This shows that the bioscaffold has the most ideal sustained release efficiency when the PAMAM concentration is 10 mg / ml.
[0045] (7) By Figure 8 It can be seen that compared with other groups of biological scaffolds, the PAMAM grafted scaffold has better clinical operability. The suture shear test shows good knotting performance, and the shear force that the P10OC@bFGF group can withstand in the wet state is significantly greater than that of other groups. In addition, the compression cycle test shows that the P10OC@bFGF group also has the best compression strength. These important mechanical properties demonstrate its good mechanical properties and clinical operability. Based on the above performance, the optimal concentration of PAMAM loaded on the biological scaffold is screened to be 10 mg / ml.
[0046] (8) By Fig. 9 It can be seen that the CCK-8 experiment showed that compared with the scaffolds not loaded with bFGF (Col, OSA-Col, POC), the groups with different growth factor concentrations (50, 100, 150 ng / ml) had higher proliferation activity of gingival fibroblasts, among which the POC@bFGF10 group had the strongest ability to promote cell proliferation.
[0047] (9) By Fig.10 It can be seen that the dead cells in each group are negligible, indicating that the scaffolds in each group are not cytotoxic. The number of live cells in the group with added growth factors is significantly higher than that in the scaffolds without bFGF (Col, OSA-Col, POC), among which the POC@bFGF10 group has the largest number of live cells, indicating that the biological scaffolds with the corresponding concentration of growth factors have the best cell proliferation ability for gingival fibroblasts.
Claims
1. A method for preparing a collagen matrix flap covalently bound with fibroblast growth factor, characterized in that: The following steps are involved: Step 1: Mix collagen and oxidized natural polysaccharides, cross-link the amino groups of collagen and the aldehyde groups of oxidized natural polysaccharides through Schiff base, and simultaneously form a gel through self-assembly of collagen, and freeze-dry to obtain a collagen cross-linked oxidized natural polysaccharide scaffold; Step 2: Immerse the collagen cross-linked oxidized natural polysaccharide scaffold in a MES buffer solution containing polyamide-amine dendrimer and growth factor, add a cross-linking agent to carry out a cross-linking reaction, and freeze-dry again after the reaction to obtain a collagen matrix flap covalently bound to fibroblast growth factor.
2. The method according to claim 1, characterized in that The oxidized natural polysaccharide is oxidized sodium alginate, oxidized corn starch or oxidized chitosan.
3. The method according to claim 1, characterized in that: The mass ratio of the oxidized natural polysaccharide to collagen is 4-20:
100.
4. The method according to claim 3, characterized in that The mass ratio of the oxidized natural polysaccharide to collagen is 16:
100.
5. The method according to claim 1, characterized in that The concentration of the polyamidoamine dendrimer is 5-20 mg / ml.
6. The method according to claim 5, characterized in that The concentration of the polyamidoamine dendrimer was 10 mg / ml.
7. The method according to claim 1, characterized in that The growth factor is basic fibroblast growth factor, and the concentration is 50-150 ng / ml.
8. The method according to claim 7, characterized in that The concentration of the growth factor was 100 ng / ml.
9. The method according to claim 1, characterized in that: The cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) cross-linking agent.
10. A collagen matrix flap covalently bound with fibroblast growth factor prepared by the method according to any one of claims 1 to 9.
Citation Information
Patent Citations
Conjugate of collagen material and growth factor as well as preparation method thereof
CN101962409B
Method for preparing graphene oxide film for sustained release of and graphene oxide film product
CN104189910A
Medicine-loaded nanoparticle vector and temperature-sensitive gel compounding system and preparation method thereof
CN106512019A
Polymer loaded with penicillin and nitric oxide at same time as well as preparation method and application of polymer
CN108969769A
Scaffold material capable of recruiting endogenous mesenchymal stem cells as well as preparation method and application thereof
CN113975461A
